1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Epiomic Epidemiology Series: Wegener’s Granulomatosis Forecast in 9 Major Markets 2015-2025

Summary

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Wegener’s Granulomatosis in 9 Major Markets
Wegener’s Granulomatosis (WG), also known as granulomatous with polyangiitis, is an autoimmune disease, involving necrotizing vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). WG primarily involves the upper and lower respiratory tracts and kidneys and originates from an inherited genetic component coupled with an unknown environment stimulus. This report provides the current prevalent population for WG across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of WG have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for WG include:

-Renal complications
-Other autoimmune conditions
-Respiratory complications
-Neurological complications
-Various vascular manifestations
-Deafness

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global WG’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of WG and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on WG’s prevalent population.
-Identify sub-populations within WG which require treatment.
-Gain an understanding of the specific markets that have the largest number of WG patients.

Table Of Contents

Epiomic Epidemiology Series: Wegener’s Granulomatosis Forecast in 9 Major Markets 2015-2025
Wegener's Granulomatosis
Table of Contents

-List of Tables and Figures
-Overview
-Introduction
-Cause of the Disease
-Risk Factors and Prevention
-Diagnosis of the Disease
-Variation by Geography/Ethnicity
-Disease Prognosis andClinical Course
-Key Co-morbid Conditions/Features Associated with the Disease
-Methodology for Quantification of Patient Numbers
-Top-Line Prevalence for Wegener's Granulomatosis
-Main Complications and Presenting Features of Wegener's Granulomatosis
o Vascular Manifestations
o ANCA Serology Status
o Respiratory Complications of Wegner's Granulomatosis
o ENT Features of Wegner's Granulomatosis
o Neurological Features of Wegner's Granulomatosis
o Renal Involvement of Wegner's Granulomatosis
-References
-Appendix

List of Tables and Figures
-Prevalence of WG, total (000s)
-Prevalence of WG, males (000s)
-Prevalence of WG, females (000s)
-WG by vascular manifestation, total (000s)
-ANCA serology status at presentation for WG, total (000s)
-Respiratory infiltrates and effusions in patients with WG, total (000s)
-Presence of lung inflammation in patients with WG, total (000s)
-ENT features at presentation of patients with WG, total (000s)
-Neurological involvement at presentation of patients with WG, total (000s)
-Presence of abnormal glomeruli in patients with WG, total (000s)
-USA Prevalence of WG by 5-yr age cohort, males (000s)
-USA Prevalence of WG by 5-yr age cohort, females (000s)
-France Prevalence of WG by 5-yr age cohort, males (000s)
-France Prevalence of WG by 5-yr age cohort, females (000s)
-Germany Prevalence of WG by 5-yr age cohort, males (000s)
-Germany Prevalence of WG by 5-yr age cohort, females (000s)
-Italy Prevalence of WG by 5-yr age cohort, males (000s)
-Italy Prevalence of WG by 5-yr age cohort, females (000s)
-Spain Prevalence of WG by 5-yr age cohort, males (000s)
-Spain Prevalence of WG by 5-yr age cohort, females (000s)
-United Kingdom Prevalence of WG by 5-yr age cohort, males (000s)
-United Kingdom Prevalence of WG by 5-yr age cohort, females (000s)
-Brazil Prevalence of WG by 5-yr age cohort, males (000s)
-Brazil Prevalence of WG by 5-yr age cohort, females (000s)
-Japan Prevalence of WG by 5-yr age cohort, males (000s)
-Japan Prevalence of WG by 5-yr age cohort, females (000s)
-India Prevalence of WG by 5-yr age cohort, males (000s)
-India Prevalence of WG by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.